SMC Decisions — April 2026

The SMC accepted five medicines and rejected one at its April 2026 meeting: Osimertinib (Tagrisso®) — Accepted for locally advanced non-small cell lung cancer with specific mutations. Pembrolizumab (Keytruda®) with chemoradiotherapy — Accepted for locally advanced cervical cancer. Sotatercept (Winrevair®) — Accepted for pulmonary arterial hypertension. Nemolizumab (Nemluvio®) — Accepted for moderate to severe atopic […]

New Framework Agreement on Supply and Pricing of Medicines (FASPM) 2026–2029

A new Framework Agreement on the Supply and Pricing of Medicines between the HSE and the Irish Pharmaceutical Healthcare Association (IPHA) took effect from 1 January 2026 and runs to 31 December 2029. Key provisions include: Horizon scanning: pharmaceutical companies must notify the HSE of new medicines 12–18 months in advance of expected launch. Rebate […]